

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC

Form 8-K

November 19, 2003

=====

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
November 18, 2003

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State of Formation)

000-30975
(Commission File Number)

911789357
(IRS Employer Identification Number)

12325 Emmet Street
Omaha, NE
(Address of principal executive offices)

68164
(Zip Code)

(402) 452-5400
(Registrants' telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Item 5. Other Events and Regulation FD Disclosure.

On November 18, 2003, the Company issued a press release announcing it has signed a contract with Austrian vaccine developer Intercell AG to develop a manufacturing process for production of an immune stimulating oligonucleotide, which will be used as a component of one or more of Intercell's novel vaccine candidates. The Company is attaching the press release as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release, dated November 18, 2003, announcing Transgenomic has signed a contract with Austrian vaccine developer Intercell AG to develop a manufacturing process for production of an immune stimulating oligonucleotide, which will be used as a component of one or more of Intercell's novel vaccine candidates.

Edgar Filing: TRANSGENOMIC INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Michael J. Draper

Michael J. Draper, Chief Financial Officer

November 18, 2003